ArticleThe Journal of antibiotics2018
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
Article in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- 5-aminosalicylic acid alleviates colitis and protects intestinal barrier function by modulating gut microbiota in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Investigating the effects of vitamin D3 and 5-aminosalicylic acid (Mesalazine) on the expression of virulence determinants inGastroenterology and hepatology from bed to bench · 2025Article
- Current understandings of colibactin regulation.Microbiology (Reading, England) · 2024Review
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- Role of adherent invasiveWorld journal of clinical cases · 2022Review
- Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.Biomedicines · 2022Review
- Gastrointestinal dysbiosis and Escherichia coli pathobionts in inflammatory bowel diseases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Microenvironmental Factors that Shape Bacterial Metabolites in Inflammatory Bowel Disease.Frontiers in cellular and infection microbiology · 2022Review
- Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?Toxins · 2021Review
- Ostarine attenuates pyocyanin in Pseudomonas aeruginosa by interfering with quorum sensing systems.The Journal of antibiotics · 2021Article
- Microbiota and Drug Response in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2021Review
- Article
- Escherichia coli-associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling.Journal of veterinary internal medicine · 2021Article
- The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin.mSphere · 2020Article
- Involvement ofInternational journal of molecular sciences · 2020Review
- Short Chain Fatty Acids Modulate the Growth and Virulence of PathosymbiontAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.Journal of translational medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflammation-associated colorectal cancer (CRC). Its clinical effect is widely attributed to modulation of host inflammatory responses. However, the recent association of intestinal dysbiosis and selective enrichment in Escherichia coli in patients with IBD and CRC raises the possibility that 5-ASA might also affect the enteric microflora. The aim of this study was to investigate the effect of 5-ASA on the growth and virulence of E. coli associated with IBD and CRC, and its impact on host cell inflammatory responses. Our results show that 5-ASA inhibited E. coli growth in a dose-dependent manner and downregulated the expression of bacterial virulence genes associated with IBD (fliC, fimH, ompC, yfgL, nlpL, lpfA, htrA, dsbA, fyuA, and chuA) and CRC (pks). 5-ASA inhibited E. coli motility (30-70%), epithelial adherence and invasion, and IL-8 secretion (p < 0.05). 5-ASA reduced E. coli survival in J774A.1 macrophages by 20 to 50% (p < 0.01) and TNF-α secretion by infected macrophages up to 30% (p < 0.05). In addition, 5-ASA reduced DNA damage in epithelial cells (Caco-2) induced by pks-positive E. coli. Our results reveal a multifaceted and previously unrecognized effect of 5-ASA on the growth and virulence of IBD- and CRC-associated E. coli, in addition to its inhibitory effect on host cell inflammatory responses. These results suggest that 5-ASA may abrogate the proinflammatory and oncogenic effects of E. coli in patients with IBD and CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.